BioNTech SE studies an RNA COVID-19 Vaccine in children <12 years

The company BioNTech SE is enrolling patients into the clinical trial investigating Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age.

This is a Phase 1/2/3 study in healthy children <12 years of age. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants <6 months of age may subsequently be evaluated.

The trial is designed to enroll male and female 6 Months to 11 Years. The study start date is March 24, 2021.

This page provides a more detailed overview of inclusion and exclusion criteria, as well as locations of this clinical trial:

Clinical Research News

Upcoming Clinical Trials